Physician profile
Marcel Perl
NPI 1619396173
$4,852.82
in general payments reported to CMS, 2019-2025
24 companies · $1,422 in 2025
The $1,422 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $253 · 2021: $11.36 · 2022: $649 · 2023: $922 · 2024: $997 · 2025: $1,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,031 · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,031.49 |
| Education | $310.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $938.92 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $804.25 | 2019-2025 | |
| Genzyme Corporation | $468.73 | 2019-2025 | |
| Pfizer INC. | $365.59 | 2019-2025 | |
| Lilly USA, LLC | $335.98 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $247.06 | 2024-2025 | Bimzelx |
| Incyte Corporation | $210.44 | 2022-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $184.53 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $183.85 | 2019-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $167.43 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $138.63 | 2019-2025 | Nemluvio, Dysport, Oracea |
| Arcutis Biotherapeutics, INC. | $136.65 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $118.97 | 2022-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $110.50 | 2019-2025 | |
| Welch Allyn | $100.00 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $95.76 | 2022-2025 | |
| Amgen INC. | $58.97 | 2025 | Otezla |
| Otsuka America Pharmaceutical, INC. | $41.79 | 2023-2024 | Rexulti, Abilify Maintena |
| Dermavant Sciences, INC. | $33.80 | 2024 | Vtama |
| Dynavax Technologies Corporation | $27.96 | 2023 | Heplisav-B |
| Organon LLC | $27.24 | 2025 | |
| Verrica Pharmaceuticals INC. | $24.06 | 2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $18.76 | 2019 | |
| Gilead Sciences, INC. | $12.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcel Perl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.